Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 20;23(9):4556. doi: 10.3390/ijms23094556

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

(A) Kaplan–Meier cumulative survival curves for GPR55(−−) and GPR55(++) patients. All 121 CC patients are included. Each patient is represented by the lymph node with the lowest GPR55 mRNA value. A GPR55 mRNA/CEA mRNA ratio of 0.1481 was used to divide the patients into two groups. (B) Kaplan–Meier cumulative survival curves for GPR55(−−) and GPR55(++) patients. The analysis is restricted to patients with CXCL16 mRNA levels in the highest lymph node > 7.2 mRNA copies/18S rRNA unit. The number of patients was 48. A GPR55 mRNA/CEA mRNA ratio of 0.1481 was used to divide the patients into two groups. (C) Kaplan–Meier cumulative survival curves for GPR55(−−) and GPR55(++) patients. The analysis is restricted to the CXCL17 mRNA levels in the highest lymph node < 0.0014 mRNA copies/18S rRNA unit. The number of patients was 91. A GPR55 mRNA/CEA mRNA ratio of 0.1481 was used to divide the patients into two groups. The patients were followed for 12 years. Differences in disease-free survival time after surgery between the two groups are given as a ∆-value in months and statistical significance as p-values; n = number of patients in the respective group.